Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04771130
Registration number
NCT04771130
Ethics application status
Date submitted
23/02/2021
Date registered
25/02/2021
Date last updated
19/10/2023
Titles & IDs
Public title
A Study of BGB-11417 in Participants With Myeloid Malignancies
Query!
Scientific title
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies
Query!
Secondary ID [1]
0
0
2021-003285-12
Query!
Secondary ID [2]
0
0
BGB-11417-103
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Acute Myeloid Leukemia
0
0
Query!
Myelodysplastic Syndromes
0
0
Query!
Myelodysplastic/Myeloproliferative Neoplasm
0
0
Query!
Condition category
Condition code
Blood
0
0
0
0
Query!
Haematological diseases
Query!
Blood
0
0
0
0
Query!
Other blood disorders
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - BGB-11417
Treatment: Drugs - Azacitidine
Treatment: Drugs - Posaconazole
Treatment: Drugs - BGB-11417
Treatment: Drugs - BGB-11417
Experimental: Parts 1 and 2: AML Cohorts - Participants with AML will receive BGB-11417 and azacitidine on a 28-day cycle.
Experimental: Parts 1 and 2: MDS Cohorts - Participants with MDS will receive BGB-11417 and azacitidine on a 28-day cycle.
Experimental: Part 3: AML and MDS Cohorts - Participants with AML and MDS will receive BGB-11417 and azacitidine on a 28-day cycle. A subset of the participants will receive a modified second cycle of treatment to explore drug-drug interactions (DDI) with posaconazole.
Experimental: Part 3: AML and MDS Cohort - Participants with MDS and R/R AML (China only) will receive BGB-11417 on a 28-day cycle.
Treatment: Drugs: BGB-11417
Oral administration for 10, 21, 14 or 28 days on a 28-day cycle.
Treatment: Drugs: Azacitidine
Intravenous or subcutaneous administration for 7 days.
Treatment: Drugs: Posaconazole
Oral administration for 8 days on second cycle only.
Treatment: Drugs: BGB-11417
Oral administration for 28 days on a 28-day cycle.
Treatment: Drugs: BGB-11417
Oral administration for 10 or 21 days on a 28-day
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Part 1 And 2: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Cycle 1 (Up to 28 days for non-hematologic DLTs and up to 42 days for hematologic DLTs)
Query!
Primary outcome [2]
0
0
Part 1 And 2: Number Of Participants Receiving BGB-11417 In Combination With Azacitidine Experiencing Treatment-emergent Adverse Events (TEAEs)
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Approximately 24 months
Query!
Primary outcome [3]
0
0
Part 3 AML Cohort: Complete Remission (CR) Plus CR With Partial Hematologic Recovery (CRh) Rate
Query!
Assessment method [3]
0
0
CR plus CRh will be defined as the proportion of participants whose best overall response (BOR) is CR plus CRh. BOR will be defined as the best response recorded from the first dose of study drug until data cut or the initiation of new anticancer treatment.
Query!
Timepoint [3]
0
0
Approximately 24 months
Query!
Primary outcome [4]
0
0
Part 3 MDS Cohort: Modified Overall Response (mOR) Rate
Query!
Assessment method [4]
0
0
The mOR will be defined as the proportion of participants whose BOR is achieving CR, marrow complete remission (mCR), or partial remission (PR) at any time point during the study for myelodysplastic/myeloproliferative neoplasm (MDS/MPN).
Query!
Timepoint [4]
0
0
Approximately 24 months
Query!
Primary outcome [5]
0
0
Part 3 AML Cohort (DDI Sub-cohort): Area Under Plasma Concentration-time Curve (AUC) from time 0 to the last quantifiable (AUC0-t) Of BGB-11417 When Co-administered With Posaconazole
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 2, 4, 6, 8, and 24 hours postdose)
Query!
Primary outcome [6]
0
0
Part 3 AML Cohort (DDI Sub-cohort): Maximum Observed Plasma Concentration (Cmax) Of BGB-11417 When Coadministered With Posaconazole
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 2, 4, 6, 8, and 24 hours postdose)
Query!
Primary outcome [7]
0
0
Part 3 AML Cohort (DDI Sub-cohort): Area Under Plasma Concentration-time Curve (AUC) from time 0 to infinity (AUC0-infinity) Of BGB-11417 When Co-administered With Posaconazole
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, , 4, 6, 8, and 24 hours postdose)
Query!
Primary outcome [8]
0
0
Part 3 AML and MDS Cohorts (Treated with Monotherapy): Number Of Participants Experiencing DLTs
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Cycle 2
Query!
Primary outcome [9]
0
0
Part 3 AML and MDS Cohorts (Treated with Monotherapy): Number of Participants Experiencing TEAEs
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
Approximately 24 months
Query!
Secondary outcome [1]
0
0
Parts 1 And 2 AML Cohort: CR Plus CRh Rate
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Approximately 24 months
Query!
Secondary outcome [2]
0
0
Parts 1 And 2 MDS Cohort: mOR Rate
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Approximately 24 months
Query!
Secondary outcome [3]
0
0
Parts 1 And 2: Cmax Of Azacitidine When Coadministered With BGB-11417
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose
Query!
Secondary outcome [4]
0
0
Parts 1 And 2: t1/2 Of Azacitidine When Coadministered With BGB-11417
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose
Query!
Secondary outcome [5]
0
0
Parts 1 And 2: AUC From Time Zero To Time t (AUC0-t) Of Azacitidine When Coadministered With BGB-11417
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose
Query!
Secondary outcome [6]
0
0
Parts 1 And 2: AUC From Time Zero To Infinity (AUC0-inf) Of Azacitidine When Coadministered With BGB-11417
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose
Query!
Secondary outcome [7]
0
0
Parts 1 And 2: Apparent Total Clearance Of Drug From Plasma After Oral Administration (CL/F) Of Azacitidine When Coadministered With BGB-11417
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose
Query!
Secondary outcome [8]
0
0
Parts 1 And 2: Apparent Volume Of Distribution (Vz/F) Of Azacitidine When Coadministered With BGB-11417
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose
Query!
Secondary outcome [9]
0
0
Parts 1 And 2: Steady-state AUC From Time Zero To Time Of Last Measurable Concentration (AUClast,ss) Of BGB-11417 When Coadministered With Azacitidine
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose
Query!
Secondary outcome [10]
0
0
Parts 1 And 2: Steady-state Cmax (Cmax,ss) Of BGB-11417 When Coadministered With Azacitidine
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose
Query!
Secondary outcome [11]
0
0
Parts 1 And 2: Steady-state Trough Plasma Concentration (Ctrough,ss) Of BGB-11417 When Coadministered With Azacitidine
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose
Query!
Secondary outcome [12]
0
0
Parts 1 And 2: Steady-state Time To Maximum Observed Plasma Concentration (tmax,ss) Of BGB-11417 When Coadministered With Azacitidine
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose
Query!
Secondary outcome [13]
0
0
Part 3: Number Of Participants Receiving BGB-11417 In Combination With Azacitidine Experiencing TEAEs
Query!
Assessment method [13]
0
0
Query!
Timepoint [13]
0
0
Approximately 24 months
Query!
Secondary outcome [14]
0
0
Part 3: Complete Response
Query!
Assessment method [14]
0
0
CR will be defined as the proportion of participants whose BOR is CR. BOR will be defined as the best response recorded from the first dose of study drug until data cut or the initiation of new anticancer treatment.
Query!
Timepoint [14]
0
0
Approximately 24 months
Query!
Secondary outcome [15]
0
0
Part 3 AML Cohort: CR With Incomplete Hematologic Recovery (CRi) Rate
Query!
Assessment method [15]
0
0
CRi will be defined as the proportion of participants whose BOR is CRi.
Query!
Timepoint [15]
0
0
Approximately 24 months
Query!
Secondary outcome [16]
0
0
Part 3 AML Cohort: Overall Response Rate (ORR)
Query!
Assessment method [16]
0
0
The ORR will include participants whose BOR include CR, CRi, PR, and morphologic leukemia-free state.
Query!
Timepoint [16]
0
0
Approximately 24 months
Query!
Secondary outcome [17]
0
0
Part 3 AML Cohort: Duration Of Response (DOR)
Query!
Assessment method [17]
0
0
DOR will be defined as the time from the first response to disease progression documented after treatment initiation or death, whichever occurs first. DOR will include CR, CR plus CRi, overall response (OR), and CR plus CRh.
Query!
Timepoint [17]
0
0
Approximately 24 months
Query!
Secondary outcome [18]
0
0
Part 3 AML Cohort: Time To Response (TTR)
Query!
Assessment method [18]
0
0
TTR will be defined as the time from treatment initiation to the first documented response and will include CR, CR plus CRi, OR, and CR plus CRh.
Query!
Timepoint [18]
0
0
Approximately 24 months
Query!
Secondary outcome [19]
0
0
Part 3 AML Cohort: Event-free Survival (EFS)
Query!
Assessment method [19]
0
0
EFS will be defined as the time from treatment initiation to disease progression, treatment failure, relapse (hematologic relapse for AML) for those who have treatment success, or death due to any cause, whichever happens first.
Query!
Timepoint [19]
0
0
Approximately 24 months
Query!
Secondary outcome [20]
0
0
Part 3 AML Cohort: Overall Survival (OS)
Query!
Assessment method [20]
0
0
OS will be defined as the time from treatment initiation to death. OS will be analyzed using the same methods as the EFS analysis except for the censoring rules.
Query!
Timepoint [20]
0
0
Approximately 24 months
Query!
Secondary outcome [21]
0
0
Part 3 AML Cohort: Number Of Participants Receiving BGB-11417 In Combination With Posaconazole Experiencing TEAEs
Query!
Assessment method [21]
0
0
Query!
Timepoint [21]
0
0
Approximately 24 months
Query!
Secondary outcome [22]
0
0
Part 3 AML Cohort: Number of Participants with Transfusion Independence
Query!
Assessment method [22]
0
0
Transfusion independence will be defined as the proportion of participants whose BOR is transfusion independence. Transfusion independence will need to last for at least 56 consecutive days postbaseline.
Query!
Timepoint [22]
0
0
Approximately 24 months
Query!
Secondary outcome [23]
0
0
Part 3 MDS Cohort: Number Of Participants With Hematological Improvement-erythroid (HI-E)
Query!
Assessment method [23]
0
0
The proportion of participants whose BOR is HI-E
Query!
Timepoint [23]
0
0
Approximately 24 months
Query!
Secondary outcome [24]
0
0
Part 3 MDS Cohort: Proportion Of Participants With Hematological Improvement-platelet (HI-P)
Query!
Assessment method [24]
0
0
The proportion of participants whose BOR is HI-P
Query!
Timepoint [24]
0
0
Approximately 24 months
Query!
Secondary outcome [25]
0
0
Part 3 MDS Cohort: Proportion Of Participants With Hematological Improvement-neutrophil (HI-N)
Query!
Assessment method [25]
0
0
The proportion of participants whose BOR is HI-N will be reported.
Query!
Timepoint [25]
0
0
Approximately 24 months
Query!
Secondary outcome [26]
0
0
Part 3 MDS Cohort: Number of participants with Transfusion Independence
Query!
Assessment method [26]
0
0
Transfusion independence will be defined as the proportion of participants whose BOR is transfusion independence. Transfusion independence will need to last for at least 56 consecutive days postbaseline.
Query!
Timepoint [26]
0
0
Approximately 24 months
Query!
Secondary outcome [27]
0
0
Part 3: Ctrough,ss Of BGB-11417 When Coadministered With Azacitidine
Query!
Assessment method [27]
0
0
Query!
Timepoint [27]
0
0
Cycle 1 Day 1 and Cycle 2 Day 5 (predose and 4 and 6 hours postdose)
Query!
Secondary outcome [28]
0
0
Part 3 MDS cohort: Partial Hematologic Recovery CRh
Query!
Assessment method [28]
0
0
Proportion of participants with partial hematologic recovery will be reported
Query!
Timepoint [28]
0
0
Approximately 24 months
Query!
Secondary outcome [29]
0
0
Part 3 AML (Treated with Monotherapy): Complete Response + Morphologic complete Remission with Partial Hematologic Recovery
Query!
Assessment method [29]
0
0
Proportion of participants with Complete Response + Morphologic complete Remission with Partial Hematologic Recovery will be reported.
Query!
Timepoint [29]
0
0
Approximately 24 months
Query!
Secondary outcome [30]
0
0
Part 3 AML (Treated with Monotherapy): Steady State trough plasma concentration of BGB-11417
Query!
Assessment method [30]
0
0
Query!
Timepoint [30]
0
0
Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 4, 6, 8, and 24 hours postdose)
Query!
Secondary outcome [31]
0
0
Part 3 MDS (Treated with Monotherapy): Modified Overall Response
Query!
Assessment method [31]
0
0
Proportion of participants with modified overall response including CR, marrow CR (mCR) or partial remission (PR)
Query!
Timepoint [31]
0
0
Approximately 24 months
Query!
Secondary outcome [32]
0
0
Part 3 MDS (Treated with Monotherapy): Steady State trough plasma concentration of BGB-11417
Query!
Assessment method [32]
0
0
Query!
Timepoint [32]
0
0
Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 4, 6, 8, and 24 hours postdose)
Query!
Eligibility
Key inclusion criteria
Key
1. Confirmed diagnosis of one of the following by 2016 World Health Organization
criteria:
- AML, nonacute promyelocytic leukemia
- MDS
- MDS/MPN
2. Eastern Cooperative Oncology Group performance status of 0 to 2.
3. Adequate organ function defined as:
- Creatinine clearance = 50 milliliters/minute (mL/min) (or between 30 and 49
mL/min in unfit AML cohort)
- Adequate liver function
4. Life expectancy of > 12 weeks.
5. Ability to comply with the requirements of the study.
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. A diagnosis of acute promyelocytic leukemia.
2. Prior malignancy within the past 2 years, except for curatively treated localized skin
cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or
localized Gleason score = 6 prostate cancer.
3. Antecedent MPN including myelofibrosis, essential thrombocytosis, polycythemia vera,
or chronic myelogenous leukemia with or without BCR-ABL1 translocation and AML with
BCR-ABL1 translocation.
4. Prior therapy with a B-cell lymphoma-2 inhibitor or azacitidine except for
participants who meet HMA-failure criteria
5. Known central nervous system involvement by leukemia.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1/Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
24/05/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/08/2025
Query!
Actual
Query!
Sample size
Target
260
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Concord Repatriation General Hospital - Concord
Query!
Recruitment hospital [2]
0
0
St George Hospital - Kogarah
Query!
Recruitment hospital [3]
0
0
Orange Health Hospital - Orange
Query!
Recruitment hospital [4]
0
0
Gold Coast University Hospital - Southport
Query!
Recruitment hospital [5]
0
0
John Flynn Private Hospital - Tugun
Query!
Recruitment hospital [6]
0
0
Monash Health - Clayton
Query!
Recruitment hospital [7]
0
0
St Vincents Hospital Melbourne - Fitzroy
Query!
Recruitment hospital [8]
0
0
Austin Health - Heidelberg
Query!
Recruitment hospital [9]
0
0
The Alfred Hospital - Melbourne
Query!
Recruitment hospital [10]
0
0
Fiona Stanley Hospital - Murdoch
Query!
Recruitment hospital [11]
0
0
Linear Clinical Research - Nedlands
Query!
Recruitment hospital [12]
0
0
One Clinical Research - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2139 - Concord
Query!
Recruitment postcode(s) [2]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [3]
0
0
2800 - Orange
Query!
Recruitment postcode(s) [4]
0
0
4215 - Southport
Query!
Recruitment postcode(s) [5]
0
0
4224 - Tugun
Query!
Recruitment postcode(s) [6]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [7]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [8]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [9]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [10]
0
0
6150 - Murdoch
Query!
Recruitment postcode(s) [11]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Maryland
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Pennsylvania
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Texas
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Wisconsin
Query!
Country [7]
0
0
China
Query!
State/province [7]
0
0
Beijing
Query!
Country [8]
0
0
China
Query!
State/province [8]
0
0
Gansu
Query!
Country [9]
0
0
China
Query!
State/province [9]
0
0
Guangdong
Query!
Country [10]
0
0
China
Query!
State/province [10]
0
0
Henan
Query!
Country [11]
0
0
China
Query!
State/province [11]
0
0
Hubei
Query!
Country [12]
0
0
China
Query!
State/province [12]
0
0
Jiangsu
Query!
Country [13]
0
0
China
Query!
State/province [13]
0
0
Jiangxi
Query!
Country [14]
0
0
China
Query!
State/province [14]
0
0
Sichuan
Query!
Country [15]
0
0
China
Query!
State/province [15]
0
0
Tianjin
Query!
Country [16]
0
0
China
Query!
State/province [16]
0
0
Zhejiang
Query!
Country [17]
0
0
Germany
Query!
State/province [17]
0
0
Leipzig
Query!
Country [18]
0
0
Korea, Republic of
Query!
State/province [18]
0
0
Seoul Teugbyeolsi
Query!
Country [19]
0
0
New Zealand
Query!
State/province [19]
0
0
Takapuna
Query!
Country [20]
0
0
New Zealand
Query!
State/province [20]
0
0
Wellington
Query!
Country [21]
0
0
Spain
Query!
State/province [21]
0
0
Barcelona
Query!
Country [22]
0
0
Spain
Query!
State/province [22]
0
0
Salamanca
Query!
Country [23]
0
0
Spain
Query!
State/province [23]
0
0
Sevilla
Query!
Country [24]
0
0
Spain
Query!
State/province [24]
0
0
Valencia
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
BeiGene
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and
preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in
participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or
MDS/myeloproliferative neoplasm (MPN) .
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04771130
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
BeiGene
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1.877.828.5568
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04771130
Download to PDF